HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4-(4'-chlorobenzyloxy)benzyl nicotinate

structure given in first source

Also Known As:

KCD 232; KCD-232

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - 4-(4'-chlorobenzyloxy)benzyl nicotinate: 3
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - 4-(4'-chlorobenzyloxy)benzyl nicotinate: 3

Related Diseases

1.	Hypertriglyceridemia 05/01/1985 - "These results suggest that 1. DR-induced hypercholesterolemia is due to both an increased Ch synthesis in the liver and delayed clearance of Ch from the circulation; 2. DR-induced hypertriglyceridemia is caused by both an increased hepatic FA synthesis and depressed TG hydrolysis in the circulation; 3. KCD-232 improves the hypercholesterolemia by inhibiting the elevated Ch synthesis and Ch absorption from the gut; and 4. KCD-232 improves the hypertriglyceridemia by inhibiting the elevated hepatic FA synthesis and by stimulating both hepatic FA oxidation and TG hydrolysis activity in the circulation." 05/01/1985 - "KCD-232 improved the hypercholesterolemia and hypertriglyceridemia of DR-treated rats. " 05/01/1985 - "Mechanisms for hypercholesterolemia and hypertriglyceridemia and the effects of KCD-232, a new hypolipidemic agent, on them were studied in male Wistar rats with daunorubicin (DR)-induced nephrosis. "
2.	Hypercholesterolemia 05/01/1985 - "These results suggest that 1. DR-induced hypercholesterolemia is due to both an increased Ch synthesis in the liver and delayed clearance of Ch from the circulation; 2. DR-induced hypertriglyceridemia is caused by both an increased hepatic FA synthesis and depressed TG hydrolysis in the circulation; 3. KCD-232 improves the hypercholesterolemia by inhibiting the elevated Ch synthesis and Ch absorption from the gut; and 4. KCD-232 improves the hypertriglyceridemia by inhibiting the elevated hepatic FA synthesis and by stimulating both hepatic FA oxidation and TG hydrolysis activity in the circulation." 05/01/1985 - "KCD-232 improved the hypercholesterolemia and hypertriglyceridemia of DR-treated rats. " 05/01/1985 - "Mechanisms for hypercholesterolemia and hypertriglyceridemia and the effects of KCD-232, a new hypolipidemic agent, on them were studied in male Wistar rats with daunorubicin (DR)-induced nephrosis. "
3.	Nephrosis 05/01/1985 - "Mechanisms for hypercholesterolemia and hypertriglyceridemia and the effects of KCD-232, a new hypolipidemic agent, on them were studied in male Wistar rats with daunorubicin (DR)-induced nephrosis. "
4.	Hyperlipidemias (Hyperlipidemia) 05/01/1985 - "[Experimental nephrotic hyperlipidemia induced in rats by daunorubicin and effects of KCD-232[4-(4'-chlorobenzyloxy)benzyl nicotinate] on lipid metabolism]."
5.	Hepatomegaly 03/01/1987 - "Hepatomegaly was induced by clofibrate, CGA, KCD-232 and MLM-160. "

Related Drugs and Biologics

1.	Hypolipidemic Agents (Antihyperlipidemics)
2.	Lipoproteins (Lipoprotein)
3.	Daunorubicin (Cerubidine)
4.	Clofibrate
5.	oxidized low density lipoprotein
6.	nicotinic acid benzyl ester

Related Therapies and Procedures

1.	Oral Administration